Selected research
Industry Research
Dry Age-Related Macular Degeneration Industry Research Report 2026
Market perspective
The global Dry Age-Related Macular Degeneration market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Dry Age-Related Macular Degeneration market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Dry Age-Related Macular Degeneration market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Dry Age-Related Macular Degeneration market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Dry Age-Related Macular Degeneration include Santen Pharmaceuticals, Y2 Solution, Stealth Biotherapeutics, Phio Pharmaceuticals, Ocumension Therapeutics, Kubota Vision, Iveric Bio, Eyestem Research and Belite Bio, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Dry Age-Related Macular Degeneration market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Dry Age-Related Macular Degeneration.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Dry Age-Related Macular Degeneration Market by Company
Santen Pharmaceuticals
Y2 Solution
Stealth Biotherapeutics
Phio Pharmaceuticals
Ocumension Therapeutics
Kubota Vision
Iveric Bio
Eyestem Research
Belite Bio
Bausch Health
Allergan
Alimera Science
Dry Age-Related Macular Degeneration Segment by Type
Oral
Injectables
Dry Age-Related Macular Degeneration Segment by Application
Above 40 Years
Above 60 Years
Above 75 Years
Dry Age-Related Macular Degeneration Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dry Age-Related Macular Degeneration market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dry Age-Related Macular Degeneration and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dry Age-Related Macular Degeneration.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Dry Age-Related Macular Degeneration companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injectables
Applications
- Above 40 Years
- Above 60 Years
- Above 75 Years
Companies covered
- Santen Pharmaceuticals
- Y2 Solution
- Stealth Biotherapeutics
- Phio Pharmaceuticals
- Ocumension Therapeutics
- Kubota Vision
- Iveric Bio
- Eyestem Research
- Belite Bio
- Bausch Health
- Allergan
- Alimera Science
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Dry Age-Related Macular Degeneration by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Oral
- 2.2.3 Injectables
- 2.3 Dry Age-Related Macular Degeneration by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Above 40 Years
- 2.3.3 Above 60 Years
- 2.3.4 Above 75 Years
- 2.4 Assumptions and Limitations
3 Dry Age-Related Macular Degeneration Breakdown Data by Type
- 3.1 Global Dry Age-Related Macular Degeneration Historic Market Size by Type (2021-2026)
- 3.2 Global Dry Age-Related Macular Degeneration Forecasted Market Size by Type (2027-2032)
4 Dry Age-Related Macular Degeneration Breakdown Data by Application
- 4.1 Global Dry Age-Related Macular Degeneration Historic Market Size by Application (2021-2026)
- 4.2 Global Dry Age-Related Macular Degeneration Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Dry Age-Related Macular Degeneration Market Perspective (2021-2032)
- 5.2 Global Dry Age-Related Macular Degeneration Growth Trends by Region
- 5.2.1 Global Dry Age-Related Macular Degeneration Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Dry Age-Related Macular Degeneration Historic Market Size by Region (2021-2026)
- 5.2.3 Dry Age-Related Macular Degeneration Forecasted Market Size by Region (2027-2032)
- 5.3 Dry Age-Related Macular Degeneration Market Dynamics
- 5.3.1 Dry Age-Related Macular Degeneration Industry Trends
- 5.3.2 Dry Age-Related Macular Degeneration Market Drivers
- 5.3.3 Dry Age-Related Macular Degeneration Market Challenges
- 5.3.4 Dry Age-Related Macular Degeneration Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Dry Age-Related Macular Degeneration Players by Revenue
- 6.1.1 Global Top Dry Age-Related Macular Degeneration Players by Revenue (2021-2026)
- 6.1.2 Global Dry Age-Related Macular Degeneration Revenue Market Share by Players (2021-2026)
- 6.2 Global Dry Age-Related Macular Degeneration Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Dry Age-Related Macular Degeneration Head Office and Area Served
- 6.4 Global Dry Age-Related Macular Degeneration Players, Product Type & Application
- 6.5 Global Dry Age-Related Macular Degeneration Manufacturers Established Date
- 6.6 Global Dry Age-Related Macular Degeneration Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Dry Age-Related Macular Degeneration Market Size (2021-2032)
- 7.2 North America Dry Age-Related Macular Degeneration Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Dry Age-Related Macular Degeneration Market Size by Country (2021-2026)
- 7.4 North America Dry Age-Related Macular Degeneration Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Dry Age-Related Macular Degeneration Market Size (2021-2032)
- 8.2 Europe Dry Age-Related Macular Degeneration Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Dry Age-Related Macular Degeneration Market Size by Country (2021-2026)
- 8.4 Europe Dry Age-Related Macular Degeneration Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Dry Age-Related Macular Degeneration Market Size (2021-2032)
- 9.2 Asia-Pacific Dry Age-Related Macular Degeneration Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Dry Age-Related Macular Degeneration Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Dry Age-Related Macular Degeneration Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Dry Age-Related Macular Degeneration Market Size (2021-2032)
- 10.2 South America Dry Age-Related Macular Degeneration Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Dry Age-Related Macular Degeneration Market Size by Country (2021-2026)
- 10.4 South America Dry Age-Related Macular Degeneration Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Dry Age-Related Macular Degeneration Market Size (2021-2032)
- 11.2 Middle East & Africa Dry Age-Related Macular Degeneration Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Dry Age-Related Macular Degeneration Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Dry Age-Related Macular Degeneration Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Santen Pharmaceuticals
- 12.1.1 Santen Pharmaceuticals Company Information
- 12.1.2 Santen Pharmaceuticals Business Overview
- 12.1.3 Santen Pharmaceuticals Revenue in Dry Age-Related Macular Degeneration Business (2021-2026)
- 12.1.4 Santen Pharmaceuticals Dry Age-Related Macular Degeneration Product Portfolio
- 12.1.5 Santen Pharmaceuticals Recent Developments
- 12.2 Y2 Solution
- 12.2.1 Y2 Solution Company Information
- 12.2.2 Y2 Solution Business Overview
- 12.2.3 Y2 Solution Revenue in Dry Age-Related Macular Degeneration Business (2021-2026)
- 12.2.4 Y2 Solution Dry Age-Related Macular Degeneration Product Portfolio
- 12.2.5 Y2 Solution Recent Developments
- 12.3 Stealth Biotherapeutics
- 12.3.1 Stealth Biotherapeutics Company Information
- 12.3.2 Stealth Biotherapeutics Business Overview
- 12.3.3 Stealth Biotherapeutics Revenue in Dry Age-Related Macular Degeneration Business (2021-2026)
- 12.3.4 Stealth Biotherapeutics Dry Age-Related Macular Degeneration Product Portfolio
- 12.3.5 Stealth Biotherapeutics Recent Developments
- 12.4 Phio Pharmaceuticals
- 12.4.1 Phio Pharmaceuticals Company Information
- 12.4.2 Phio Pharmaceuticals Business Overview
- 12.4.3 Phio Pharmaceuticals Revenue in Dry Age-Related Macular Degeneration Business (2021-2026)
- 12.4.4 Phio Pharmaceuticals Dry Age-Related Macular Degeneration Product Portfolio
- 12.4.5 Phio Pharmaceuticals Recent Developments
- 12.5 Ocumension Therapeutics
- 12.5.1 Ocumension Therapeutics Company Information
- 12.5.2 Ocumension Therapeutics Business Overview
- 12.5.3 Ocumension Therapeutics Revenue in Dry Age-Related Macular Degeneration Business (2021-2026)
- 12.5.4 Ocumension Therapeutics Dry Age-Related Macular Degeneration Product Portfolio
- 12.5.5 Ocumension Therapeutics Recent Developments
- 12.6 Kubota Vision
- 12.6.1 Kubota Vision Company Information
- 12.6.2 Kubota Vision Business Overview
- 12.6.3 Kubota Vision Revenue in Dry Age-Related Macular Degeneration Business (2021-2026)
- 12.6.4 Kubota Vision Dry Age-Related Macular Degeneration Product Portfolio
- 12.6.5 Kubota Vision Recent Developments
- 12.7 Iveric Bio
- 12.7.1 Iveric Bio Company Information
- 12.7.2 Iveric Bio Business Overview
- 12.7.3 Iveric Bio Revenue in Dry Age-Related Macular Degeneration Business (2021-2026)
- 12.7.4 Iveric Bio Dry Age-Related Macular Degeneration Product Portfolio
- 12.7.5 Iveric Bio Recent Developments
- 12.8 Eyestem Research
- 12.8.1 Eyestem Research Company Information
- 12.8.2 Eyestem Research Business Overview
- 12.8.3 Eyestem Research Revenue in Dry Age-Related Macular Degeneration Business (2021-2026)
- 12.8.4 Eyestem Research Dry Age-Related Macular Degeneration Product Portfolio
- 12.8.5 Eyestem Research Recent Developments
- 12.9 Belite Bio
- 12.9.1 Belite Bio Company Information
- 12.9.2 Belite Bio Business Overview
- 12.9.3 Belite Bio Revenue in Dry Age-Related Macular Degeneration Business (2021-2026)
- 12.9.4 Belite Bio Dry Age-Related Macular Degeneration Product Portfolio
- 12.9.5 Belite Bio Recent Developments
- 12.10 Bausch Health
- 12.10.1 Bausch Health Company Information
- 12.10.2 Bausch Health Business Overview
- 12.10.3 Bausch Health Revenue in Dry Age-Related Macular Degeneration Business (2021-2026)
- 12.10.4 Bausch Health Dry Age-Related Macular Degeneration Product Portfolio
- 12.10.5 Bausch Health Recent Developments
- 12.11 Allergan
- 12.11.1 Allergan Company Information
- 12.11.2 Allergan Business Overview
- 12.11.3 Allergan Revenue in Dry Age-Related Macular Degeneration Business (2021-2026)
- 12.11.4 Allergan Dry Age-Related Macular Degeneration Product Portfolio
- 12.11.5 Allergan Recent Developments
- 12.12 Alimera Science
- 12.12.1 Alimera Science Company Information
- 12.12.2 Alimera Science Business Overview
- 12.12.3 Alimera Science Revenue in Dry Age-Related Macular Degeneration Business (2021-2026)
- 12.12.4 Alimera Science Dry Age-Related Macular Degeneration Product Portfolio
- 12.12.5 Alimera Science Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst